N
Nolan A. Wages
Researcher at University of Virginia
Publications - 94
Citations - 1207
Nolan A. Wages is an academic researcher from University of Virginia. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 19, co-authored 73 publications receiving 904 citations. Previous affiliations of Nolan A. Wages include Hampden–Sydney College & University of Virginia Health System.
Papers
More filters
Journal ArticleDOI
Continual reassessment method for partial ordering.
TL;DR: A new two-dimensional dose-finding method for multiple-agent trials that simplifies to the continual reassessment method (CRM), introduced by O'Quigley, Pepe, and Fisher (1990, Biometrics 46, 33-48), when the ordering is fully known, enables the assumption of a monotonic dose-toxicity curve to be relaxed.
Journal ArticleDOI
Dose-finding design for multi-drug combinations:
TL;DR: A new dose-finding design which relaxes the monotonicity assumption and can serve as a link between single and multiple-agent dosefinding trials and can be considered a multivariate generalization of the CRM.
Journal ArticleDOI
Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.
Nolan A. Wages,Christopher Tait +1 more
TL;DR: A new early-phase method for trials investigating targeted agents is proposed and simulation results illustrating the operating characteristics of this design are provided.
Journal ArticleDOI
A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.
Marit M. Melssen,Gina R. Petroni,Kimberly A. Chianese-Bullock,Nolan A. Wages,William W. Grosh,Nikole Varhegyi,Mark E. Smolkin,Kelly T. Smith,Nadejda V. Galeassi,Donna H. Deacon,Elizabeth M. Gaughan,Craig L. Slingluff +11 more
TL;DR: LPS and polyICLC are safe and effective vaccine adjuvants when combined with IFA, and contrary to the central hypothesis, IFA enhanced T cell responses to peptide vaccines when added to TLR agonists.
Journal ArticleDOI
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.
Brian P. Hobbs,Pedro C. Barata,Pedro C. Barata,Yada Kanjanapan,Channing J. Paller,Jane Perlmutter,Gregory R. Pond,Tatiana M. Prowell,Tatiana M. Prowell,Eric H. Rubin,Lesley Seymour,Nolan A. Wages,Timothy A. Yap,David Feltquate,Elizabeth Garrett-Mayer,William Grossman,David S. Hong,S. Percy Ivy,Lillian L. Siu,Steven A. Reeves,Gary L. Rosner +20 more
TL;DR: All abstracts presented at American Society of Clinical Oncology annual meetings from 2010 to 2017 for FiH trials enrolling at least 100 patients are reviewed to identify seamless trials and recommend protocols of sufficient rigor to support accelerated approval.